Mimicking p14ARF Phosphorylation Influences Its Ability to Restrain Cell Proliferation

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Vivo, Maria ^a   Ranieri, Michela ^a   Sansone, Federica ^a   Santoriello, Cristina ^b   Calogero, Raffaele A ^c   Calabrò, Viola ^a   Pollice, Alessandra ^a   la Mantia, Girolama ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MUTANT PROTEIN; PROTEIN KINASE C; PROTEIN MDM2; PROTEIN P53; THREONINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BIOACCUMULATION; BIOSURVEILLANCE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATIVE STRESS; PREDICTION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TUMOR ESCAPE;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; HUMANS; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; THREONINE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872135922     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053631     Document Type: Article

References (55)

1. Muniz VP, Barnes JM, Paliwal S, Zhang X, Tang X, et al. (2011) The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis. Mol Cancer Res 9: 867-877.
2. Rodriguez P, (2004) The ARF protein in tumor suppression: lessons from mouse models and human tumors. Rev Oncol 6: 7.
3. Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T, et al. (2010) c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 29: 5687-5699.
4. Ozenne P, Eymin B, Brambilla E, Gazzeri S, (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127: 2239-2247.
5. Sherr CJ, (2006) Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673.
6. Levine AJ, Oren M, (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749-758.
7. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, et al. (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12: 2434-2442.
8. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR, (1997) Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A 94: 7245-7250.
9. Palmero I, Pantoja C, Serrano M, (1998) p19ARF links the tumour suppressor p53 to Ras. Nature 395: 125-126.
10. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433.
11. Brady CA, Attardi LD, (2010) p53 at a glance. J Cell Sci 123: 2527-2532.
12. Zhang Y, Xiong Y, (2001) Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ 12: 175-186.
13. Herkert B, Dwertmann A, Herold S, Abed M, Naud JF, et al. (2010) The Arf tumor suppressor protein inhibits Miz1 to suppress cell adhesion and induce apoptosis. J Cell Biol 188: 905-918.
14. Shen J, Zhang S, Li Y, Zhang W, Chen J, et al. (2011) p14(ARF) inhibits the functions of adenovirus E1A oncoprotein. Biochem J 434: 275-285.
15. Wang S, Tian C, Xing G, Gao M, Jiao W, et al. (2010) ARF-dependent regulation of ATM and p53 associated KZNF (Apak) protein activity in response to oncogenic stress. FEBS Lett 584: 3909-3915.
16. Pollice A, Vivo M, La Mantia G, (2008) The promiscuity of ARF interactions with the proteasome. FEBS Lett 582: 3257-3262.
17. Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, et al. (2009) The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 23: 1171-1176.
18. Aslanian A, Iaquinta PJ, Verona R, Lees JA, (2004) Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 18: 1413-1422.
19. del Arroyo AG, El Messaoudi S, Clark PA, James M, Stott F, et al. (2007) E2F-dependent induction of p14ARF during cell cycle re-entry in human T cells. Cell Cycle 6: 2697-2705.
20. Popov N, Gil J, (2010) Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. Epigenetics 5: 685-690.
21. Taneja P, Mallakin A, Matise LA, Frazier DP, Choudhary M, et al. (2007) Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-kappaB subunit p65. Oncogene 26: 7457-7466.
22. Pollice A, Sepe M, Villella VR, Tolino F, Vivo M, et al. (2007) TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation. Oncogene 26: 5154-5162.
23. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ, (2004) N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 18: 1862-1874.
24. Chen D, Shan J, Zhu WG, Qin J, Gu W, (2010) Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 464: 624-627.
25. Inoue R, Shiraishi T, (2005) PKCalpha is involved in phorbol ester TPA-mediated stabilization of p14ARF. Biochem Biophys Res Commun 330: 1314-1318.
26. Jerome-Morais A, Rahn HR, Tibudan SS, Denning MF, (2009) Role for protein kinase C-alpha in keratinocyte growth arrest. J Invest Dermatol 129: 2365-2375.
27. Clark PA, Llanos S, Peters G, (2002) Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2. Oncogene 21: 4498-4507.
28. Weber JD, Kuo ML, Bothner B, DiGiammarino EL, Kriwacki RW, et al. (2000) Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 20: 2517-2528.
29. Vivo M, Di Costanzo A, Fortugno P, Pollice A, Calabro V, et al. (2009) Downregulation of DeltaNp63alpha in keratinocytes by p14ARF-mediated SUMO-conjugation and degradation. Cell Cycle 8: 3537-3543.
30. Xue Y, Ren J, Gao X, Jin C, Wen L, et al. (2008) GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. Mol Cell Proteomics 7: 1598-1608.
31. Sim AT, Scott JD, (1999) Targeting of PKA, PKC and protein phosphatases to cellular microdomains. Cell Calcium 26: 209-217.
32. Itahana K, Zhang Y, (2008) Mitochondrial p32 is a critical mediator of ARF-induced apoptosis. Cancer Cell 13: 542-553.
33. Pollice A, Nasti V, Ronca R, Vivo M, Lo Iacono M, et al. (2004) Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1. J Biol Chem 279: 6345-6353.
34. Llanos S, Clark PA, Rowe J, Peters G, (2001) Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 3: 445-452.
35. Calabro V, Parisi T, Di Cristofano A, La Mantia G, (1999) Suppression of Ras-mediated NIH3T3 transformation by p19ARF does not involve alterations of cell growth properties. Oncogene 18: 2157-2162.
36. Hashemi J, Lindstrom MS, Asker C, Platz A, Hansson J, et al. (2002) A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. Cancer Lett 180: 211-221.
37. Adams DR, Ron D, Kiely PA, (2011) RACK1, A multifaceted scaffolding protein: Structure and function. Cell Commun Signal 9: 22.
38. Denning MF, Dlugosz AA, Williams EK, Szallasi Z, Blumberg PM, et al. (1995) Specific protein kinase C isozymes mediate the induction of keratinocyte differentiation markers by calcium. Cell Growth Differ 6: 149-157.
39. Shimao Y, Nabeshima K, Inoue T, Koono M, (1999) TPA-enhanced motility and invasion in a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1: selective role of PKC-alpha and its inhibition by a combination of PDBu-induced PKC downregulation and antisense oligonucleotides treatment. Clin Exp Metastasis 17: 351-360.
40. Dlugosz AA, Mischak H, Mushinski JF, Yuspa SH, (1992) Transcripts encoding protein kinase C-alpha,-delta,-epsilon,-zeta, and-eta are expressed in basal and differentiating mouse keratinocytes in vitro and exhibit quantitative changes in neoplastic cells. Mol Carcinog 5: 286-292.
41. Breitkreutz D, Braiman-Wiksman L, Daum N, Denning MF, Tennenbaum T, (2007) Protein kinase C family: on the crossroads of cell signaling in skin and tumor epithelium. J Cancer Res Clin Oncol 133: 793-808.
42. Efimova T, Deucher A, Kuroki T, Ohba M, Eckert RL, (2002) Novel protein kinase C isoforms regulate human keratinocyte differentiation by activating a p38 delta mitogen-activated protein kinase cascade that targets CCAAT/enhancer-binding protein alpha. J Biol Chem 277: 31753-31760.
43. Fagerstrom S, Pahlman S, Gestblom C, Nanberg E, (1996) Protein kinase C-epsilon is implicated in neurite outgrowth in differentiating human neuroblastoma cells. Cell Growth Differ 7: 775-785.
44. Wheeler DL, Reddig PJ, Ness KJ, Leith CP, Oberley TD, et al. (2005) Overexpression of protein kinase C-{epsilon} in the mouse epidermis leads to a spontaneous myeloproliferative-like disease. Am J Pathol 166: 117-126.
45. Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, et al. (2011) Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem 11: 185-199.
46. Griner EM, Kazanietz MG, (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7: 281-294.
47. di Tommaso A, Hagen J, Tompkins V, Muniz V, Dudakovic A, et al. (2009) Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. Exp Cell Res 315: 1326-1335.
48. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A, (2001) DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3: 1-7.
49. Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, et al. (2005) Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 25: 1258-1271.
50. Korgaonkar C, Zhao L, Modestou M, Quelle DE, (2002) ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 22: 196-206.
51. Rodway H, Llanos S, Rowe J, Peters G, (2004) Stability of nucleolar versus non-nucleolar forms of human p14(ARF). Oncogene 23: 6186-6192.
52. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, et al. (2005) Reverse engineering of regulatory networks in human B cells. Nat Genet 37: 382-390.
53. Vivo M, Calogero RA, Sansone F, Calabro V, Parisi T, et al. (2001) The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein. J Biol Chem 276: 14161-14169.
54. Colucci-D'Amato GL, D'Alessio A, Califano D, Cali G, Rizzo C, et al. (2000) Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK. J Biol Chem 275: 19306-19314.
55. Di Costanzo A, Festa L, Duverger O, Vivo M, Guerrini L, et al. (2009) Homeodomain protein Dlx3 induces phosphorylation-dependent p63 degradation. Cell Cycle 8: 1185-1195.